Onderzoeker
Hendrik Everaert
- Trefwoorden:Geneeskunde
- Disciplines:Nucleaire beeldvorming
Affiliaties
- Ondersteunende Klinische wetenschappen (Departement)
Lid
Vanaf1 jan 2014 → Heden - Medische Beeldvorming (Onderzoeksgroep)
Lid
Vanaf1 jan 2011 → Heden - Medische Beeldvorming en Fysische Wetenschappen (Departement)
Lid
Vanaf1 okt 2002 → 31 dec 2013 - nucleaire geneeskunde (Departement)
Lid
Vanaf1 jan 2008 → Heden
Publicaties
1 - 10 van 93
- The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression(2021)
Auteurs: Karolien Vekens, Hendrik Everaert, Bart Neyns, Bart Ilsen, Lore Decoster
Pagina's: 432-440Aantal pagina's: 9 - Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients(2021)
Auteurs: Matthias D'Huyvetter, Jens De Vos, Vicky Caveliers, Ilse Vaneycken, Johannes Heemskerk, Francois P Duhoux, Christel Fontaine, Marian Vanhoeij, Albert D Windhorst, Frank van der Aa, et al.
Pagina's: 1097-1105Aantal pagina's: 9 - Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio(2021)
Auteurs: Vincent Vinh-Hung, Hendrik Everaert, Olena Gorobets, Hilde Van Parijs, Guy Verfaillie, Marian Vanhoeij, Guy Storme, Christel Fontaine, Jan Lamote, Justine Perrin, et al.
Pagina's: 956-968Aantal pagina's: 13 - Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma(2021)
Auteurs: Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, et al.
Aantal pagina's: 11 - A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT)(2021)
Auteurs: Gil Awada, Julia Katharina Schwarze, J Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
Aantal pagina's: 13 - Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome(2021)
Auteurs: Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns, Hendrik Everaert
Pagina's: 1630-1640Aantal pagina's: 11 - A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab(2021)
Auteurs: Gil Awada, Yanina J L Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly Schats, Pieter-Jan van Dam, et al.
Pagina's: 1-18Aantal pagina's: 18 - Axitinib plus avelumab in the treatment of recurrent glioblastoma(2020)
Auteurs: Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, et al.
- Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma(2020)
Auteurs: Denis Schallier, Pierre Lesfevre, Hendrik Everaert
Pagina's: 2265-2269Aantal pagina's: 5 - An atypical sarcoid-like reaction during anti-protein death 1 treatment in a patient with metastatic melanoma(2020)
Auteurs: Stijn De Keukeleire, Julia Katharina Schwarze, Gil Awada, Hendrik Everaert, Anne-Marie Vanbinst, Louise Cras, Bart Neyns, Sandrine Aspeslagh
Pagina's: 524-527Aantal pagina's: 4